Dichlorvos (DDVP) Risk Characterization Document - California ...

Table 8.
Clinical signs and brain cholinesterase inhibition in dogs treated with DDVP in
capsules for 1 year a .
Cholinergic signs
Dosage
Occurrences b
Sex (mg/kg-day) soft stools emesis salivation ataxia dyspnea
Males and
Females 0 18
+
2
+
0
+
0 0
0.05 36 ** 4 0 0 0
1.0 42 ** 13 ** 2 0 0
3.0 40 ** 34 ** 8 1 1
Brain ChE inhibition
Dosage
Sex (mg/kg-day) % of Control c
Males 0 100
0.05 89
1.0 78 *
3.0 53 *
Females 0 100
0.05 106
1.0 93
3.0 71 *
a/
b/
c/
Data were from Markiewicz (1990).
Values are occurrences reported during the study. An occurrence is at least one observation
per week in any animal with a total possible occurrences of 416 (52 weeks x 8 animals per
group). Level of statistical significance, p @ 0.05 (* or + ) or p @ 0.01 (** or ++ ), is indicated after
each incidence. Significance at the control value is based on a dose-weighted chi-square
trend test, and significance at the dosed groups is for the Fisher's Exact Test.
Statistically significant (* p @ 0.05) from control values determined by the analysis of variance
(ANOVA) in the report.
39